Lineage Cell Therapeutics busy working on treatments relating to Dry AMD and spinal cord injury
Lineage Cell Therapeutics (NYSE AMERICAN: LCTX) CEO Brian Culley and CFO Brandi Roberts joined Steve Darling from Proactive to share details about their proprietary cell-based therapy platform. The Company is using that platform to advance a pipeline of novel candidates for the treatment of advanced dry age-related macular degeneration, spinal cord injuries, and cancer. Both Culley and Roberts discussed recent clinical developments and provided an overview of the Company’s balance sheet. Lineage will be a featured company on Proactive’s next One2One Virtual conferences.
People In This Video
No users are tagged in this video